Last reviewed · How we verify
S-488210
At a glance
| Generic name | S-488210 |
|---|---|
| Also known as | S-588210 |
| Sponsor | Shionogi |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (PHASE1, PHASE2)
- First-in-human Study of S-588210 (S-488210+S-488211) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-488210 CI brief — competitive landscape report
- S-488210 updates RSS · CI watch RSS
- Shionogi portfolio CI